Smart partnerships that advance cell and gene therapy

 
 
 
 

At Kiniciti, we empower partner companies with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.

 
 

Why Kiniciti Exists 

Promising cell and gene therapy breakthroughs deserve a vibrant scientific and business ecosystem to help them thrive. At Kiniciti, we’re committed to building partnerships that can leverage value from precisely that kind of infrastructure.

 
KINI-why-K-exists.png
 
 

Latest News & Information

Featured
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth
Cellistic And Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
Cellistic And Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including existing facility and all related personnel.

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform
Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Collaboration combines Quell's pioneering autologous multi-modular Treg cell therapy platform and Cellistic™'s expertise in iPSC cell therapy platform development and scale-up

Ncardia Launches Cellistic™ — Purpose-Built To Make Large-Scale Allogeneic Cell Therapy Production A Reality Today
Ncardia Launches Cellistic™ — Purpose-Built To Make Large-Scale Allogeneic Cell Therapy Production A Reality Today

Ncardia launches Cellistic™, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.

Ncardia Appoints Andy Holt as Chief Commercial Officer
Ncardia Appoints Andy Holt as Chief Commercial Officer

Ncardia, iPSC technology leader, taps industry veteran to drive growth in cell therapy and drug discovery markets.

Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings

Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide.

Kiniciti raises additional capital from Biospring Partners to fund its global platform serving the Cell & Gene Therapy Industry
Kiniciti raises additional capital from Biospring Partners to fund its global platform serving the Cell & Gene Therapy Industry

Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in cell and gene therapy innovation, announced today that Biospring Partners has joined WCAS as an investor in Kiniciti. Dr. Michelle Dipp, Biospring’s Managing Partner, will serve on Kiniciti’s Board of Directors.

Kiniciti Welcomes Two Cell and Gene Therapy Industry Leaders to its Advisory Board
Kiniciti Welcomes Two Cell and Gene Therapy Industry Leaders to its Advisory Board

Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in non-therapeutic companies supporting Cell and Gene Therapy innovation, announced the formation of an advisory board and appointment of two inaugural members: Denis Bedoret, PhD, chief executive officer of Imcyse, and Andrew Knudten, chief operating officer of Jaguar Gene Therapy.

Welsh, Carson, Anderson & Stowe Commits $250 Million in a Strategic Partnership with Kiniciti, a Newly-Formed Platform Investing in Cell and Gene Therapy Companies
Welsh, Carson, Anderson & Stowe Commits $250 Million in a Strategic Partnership with Kiniciti, a Newly-Formed Platform Investing in Cell and Gene Therapy Companies

Welsh, Carson, Anderson & Stowe (“WCAS”), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that it is committing up to $250 million to a strategic partnership with Kiniciti, a newly-formed platform. Kiniciti will invest in non-therapeutic companies supporting cell and gene therapy (“CGT”) innovation which have the potential to transform the cell and gene therapy ecosystem and deliver the promise of CGT to impact patients’ lives.

 
 

Where Urgency and Capability Meet

Kiniciti invests in opportunities with the potential to leverage technology and capabilities that can drive transformational change and ensure the promise of cell and gene therapies is delivered to patients in need. So we’re ready and able to pursue partnerships in:

 
 
KINI_icon_cell_source.png

Cell sources and other enabling quality-controlled starting and raw materials

 
KINI_icon_tech_platform.png

Enabling technology platforms (including cell-programming and gene-editing innovations)

 
KINI_icon_scale.png

Key tools, services and enablers for process development and scale-up

 
 
 
KINI_icon_delivery.png

Innovations and solutions from source-to-patient delivery

 
KINI_icon_plus.png
 

Other solutions designed to fulfill the promise of breakthrough treatments while concurrently reducing costs to ensure affordable access for patients

 
 
 
 

Leverage Our Advantages

 
 

Speed

A focused, nimble team with an ability to act quickly and decisively to initiate and close partnerships with no layers of bureaucracy

Resources

The backing of a $27BN investment leader with decades of experience building healthcare platforms

Flexibility

A highly tailored approach that provides an adaptable investment philosophy – created uniquely for each partnership

 
 
 
 

About Our Team

Industry intelligence. Business savvy. Serious capital. This is what Kiniciti brings to the table. Our team comprises some of the most experienced professionals in investing in and building successful companies across the Life Sciences sector.

 

Contact

We are actively working on growing and developing key partnerships throughout the cell and gene therapy market. Connect with us to explore how our team can support your short- and long-term goals.